https://scholars.lib.ntu.edu.tw/handle/123456789/634562
標題: | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) | 作者: | Zeuzem, S Flisiak, R Vierling, J M Mazur, W Mazzella, G Thongsawat, S Abdurakhmanov, D Van Kính, N Calistru, P Heo, J Stanciu, C Gould, M Makara, M SHIH-JER HSU Buggisch, P Samuel, D Mutimer, D Nault, B Merz, M Bao, W Griffel, L H Brass, C Naoumov, N V |
公開日期: | 十月-2015 | 卷: | 42 | 期: | 7 | 起(迄)頁: | 829 | 來源出版物: | Alimentary pharmacology & therapeutics | 摘要: | Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. |
URI: | https://www.scopus.com/record/display.uri?eid=2-s2.0-84940788102&doi=10.1111%2fapt.13342&origin=inward&txGid=674e144230fee461c0ee3463fde4fac1 https://scholars.lib.ntu.edu.tw/handle/123456789/634562 |
ISSN: | 02692813 | DOI: | 10.1111/apt.13342 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。